Pipeline

Strategically Built. Clinically Tested.
Advancing the Frontier of mRNA Medicines

Through clinical programs advancing from discovery into Phase II across more than 900 study participants, we have built and validated a fully integrated mRNA platform spanning payload design, targeted LNP delivery, and scalable manufacturing. This foundation enables us to move beyond early proof-of-concept programs and pursue the true promise of mRNA therapeutics: programmable protein replacement for chronic metabolic disease and targeted in vivo immunotherapies for autoimmune conditions, delivered through technologies capable of directing mRNA payloads to specific cell types throughout the body.

Clearly defined

unmet
medical need

Clinically

validated
targets

Clear

mRNA

modality advantage

Uniquely enabled by

Innorna
platform

Chronic Disease

In March, 2026, Innorna announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IN026, an investigational mRNA-based therapy for refractory gout. IN026 delivers mRNA encoding urate oxidase (uricase; UOX) to the liver to enable systemic uric acid breakdown. Engineered on Innorna's proprietary mRNA–lipid nanoparticle (LNP) platform for repeat administration and long-term disease control, IN026 represents a potential first-in-class approach to mRNA-based protein-replacement therapy for refractory gout and other chronic metabolic diseases.

In Vivo Immunotherapy

IN036 is a novel mRNA drug candidate for systemic lupus erythematosus (SLE) with potential application in other autoimmune diseases.

Infectious Disease

IN006 is the world’s first bivalent respiratory syncytial virus (RSV) mRNA vaccine, China’s first non-COVID-19 mRNA vaccine and first domestically developed RSV vaccine to enter clinical trials, targeting RSV-A and RSV-B, built on Innorna’s proprietary pre-fusion F protein design, mRNA, and LNP platforms. In September, 2025, Innorna announced the completion of enrollment and vaccination in its Phase II clinical trial for IN006.

Innorna's other mRNA vaccine pipelines include:

IN001 for herpes zoster, IN023 for herpes simplex virus type 2 (HSV-2), and IN029 for the prevention of combined respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) infection.

PROGRAM THERAPEUTIC AREA INDICATION

DISCOVERY IND-ENABLING PHASE I PHASE II PHASE III PARTNERS

IN036 is a novel mRNA drug candidate for systemic lupus erythematosus (SLE) with potential application in other autoimmune diseases.

IN001 Infectious Disease Herpes Zoster (HZ)

IN006 Infectious Disease Respiratory Syncytial Virus (RSV)

Innorna's other mRNA vaccine pipelines include:

IN001 for herpes zoster, IN023 for herpes simplex virus type 2 (HSV-2), and IN029 for the prevention of combined respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) infection.